Only Two Ring Sulfurs In The Hetero Ring Patents (Class 514/440)
  • Publication number: 20140234428
    Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 21, 2014
    Applicant: Cymbiotics, Inc.
    Inventors: Raj R. Barathur, Jack Bain Bookout
  • Publication number: 20140227242
    Abstract: Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.
    Type: Application
    Filed: April 15, 2014
    Publication date: August 14, 2014
    Inventors: Philip J. Bromley, Chetan S. Rao
  • Publication number: 20140221467
    Abstract: The invention provides mutual ternary salts of metformin, lipoic acid and acidic amino acids such as aspartic acid and glutamic acid. The invention further provides treatment of prediabetes, diabetes, diabetic complications and/or other conditions in mammals in a method that comprises administering an effective amount of one or more of the foregoing compositions to a mammal in need of such treatment.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Inventor: Banavara L. Mylari
  • Publication number: 20140186466
    Abstract: Disclosed are compositions of matter useful for the treatment of diabetes. In one embodiment a nutraceutical composition is administered to a patient in need, said composition comprising of one or more ingredients selected from a group consisting of: magnesium, chromium picolinate, alpha lipoic acid, Garcina indica, holy basil, Morodica charantica, cinnamon, Salacia reticulate, Salacia oblonga, Gymnema sylvestre, nopal cactus, fenu greek, vanadium, 1-carnitine, and vitamin D3.
    Type: Application
    Filed: December 31, 2013
    Publication date: July 3, 2014
    Applicant: Creative Medical Health Inc.
    Inventor: Amit Patel
  • Publication number: 20140155961
    Abstract: A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-l-carnitine, and l-carnosine.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: Tracie Martyn International, Inc.
    Inventor: Marius Morariu
  • Patent number: 8741941
    Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: June 3, 2014
    Assignee: Pola Pharma Inc.
    Inventors: Hideaki Sasagawa, Madoka Ito, Takuji Nakashima, Akira Nozawa
  • Patent number: 8735443
    Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: May 27, 2014
    Assignee: Kuwait University
    Inventors: Fahd Al-Mulla, Milad Bitar
  • Publication number: 20140140931
    Abstract: This invention relates to antioxidant, neuroprotective and antineoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer. Methods of synthesizing the antioxidant derivatives of camptothecin and anti-oxidant derivatives of camptothecin analogs, NSAIDs and statins, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant, neuroprotective and anti-neoplastic nanoparticles comprising a therapeutic agent on an amphiphilic spacer or an amphiphilic polymer and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these neuroprotective and anti-neoplastic nanoparticles for the preparation of delivery devices of other pharmaceuticals and/or drugs.
    Type: Application
    Filed: July 27, 2012
    Publication date: May 22, 2014
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: John S. Yu, Bong Seop Lee
  • Publication number: 20140134222
    Abstract: The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: Tracie Martyn International, Inc.
    Inventor: Marius Morariu
  • Publication number: 20140134229
    Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 15, 2014
    Applicant: KCI Licensing, Inc.
    Inventors: DMITRY ZIMNITSKY, Jenny Finkbiner, Blane Sanders
  • Publication number: 20140127272
    Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 8, 2014
    Applicant: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Bong Seop Lee
  • Publication number: 20140121266
    Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.
    Type: Application
    Filed: March 27, 2013
    Publication date: May 1, 2014
    Applicant: ENCORE HEALTH LLC
    Inventors: William Garner, Margaret Garner, George Minno, David Gooden
  • Patent number: 8709515
    Abstract: The method comprises steps of: providing a nutraceutical including, in combination, 1.13 to 3 mg lutein and 18.8 to 51.2 mg omega fatty acids and 1.9 to 5.2 mg grape seed extract and 1.9 to 5.2 mg alpha lipoic acid; determining the weight of each dose of the components in the combination based upon an amount per kg body weight of the animal patients; and administering 1 dose of nutraceutical per day to animals suffering from ocular health issues including any degenerative retinal disease and diabetic cataracts and prior to and following cataract surgery for the diminishment and prevention of secondary cataracts.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 29, 2014
    Inventors: Carmen C. H. Colitz, Terri L. McCalla, Debra A. Smith
  • Publication number: 20140107140
    Abstract: Pharmaceutical compositions and methods for the treatment of Gulf War Illness in human patients comprising administering a central nervous system (CNS) stimulant in a daily low-dosage amount, and micronutrients acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS stimulant and micronutrient components may be in admixture for convenient daily oral administration of a low dosage CNS stimulant and micronutrients in the range of about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid per day.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: K-PAX Pharmaceuticals, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8697743
    Abstract: The present invention is directed to antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs and the preparation of nanometer-sized camptothecin prodrugs. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant camptothecin nanosphere prodrugs and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these antioxidant camptothecin nanosphere prodrugs for the preparation of delivery devices of other pharmaceuticals and/or drugs. Additionally, methods of treating cancer with the camptothecin and antioxidant derivatives of camptothecin analogs, and nanometer-sized camptothecin prodrugs are also provided.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: April 15, 2014
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Bong Seop Lee
  • Publication number: 20140100267
    Abstract: Novel compounds, and in particular to diacylglycerol (1, 3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 10, 2014
    Inventor: Paresh DUTTA
  • Publication number: 20140093489
    Abstract: A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts.
    Type: Application
    Filed: September 30, 2013
    Publication date: April 3, 2014
    Inventor: Robert DiSilvestro
  • Patent number: 8673964
    Abstract: The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: March 18, 2014
    Assignee: DiaMedica Inc.
    Inventor: Wilfred Wayne Lautt
  • Patent number: 8669282
    Abstract: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: March 11, 2014
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Steven C. Zicker, Nolan Zebulon Frantz
  • Patent number: 8629175
    Abstract: Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: January 14, 2014
    Inventor: Paresh Dutta
  • Publication number: 20130337091
    Abstract: The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and ?-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease.
    Type: Application
    Filed: January 31, 2012
    Publication date: December 19, 2013
    Applicant: LUCOLAS-M.D. LTD.
    Inventor: Alfred Schmidt
  • Patent number: 8603531
    Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: December 10, 2013
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Bong Seop Lee
  • Patent number: 8592479
    Abstract: The invention encompasses compositions for enhancing the ability of a companion animal to resist and/or overcome viral infections. The compositions of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: November 26, 2013
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Steven C. Zicker, Jeffrey A. Brockman, Nolan Zebulon Frantz
  • Patent number: 8592478
    Abstract: A food composition comprises an antioxidant component comprising at least one of alpha-lipoic acid and L-carnitine, said composition meeting ordinary nutritional requirements for an adult canine or feline.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: November 26, 2013
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Steven Curtis Zicker, Karen J. Wedekind
  • Publication number: 20130309217
    Abstract: The invention relates to the use of an agent and a composition, respectively, comprising the following active ingredients: a) an aromatase inhibitor and/or a 5-?-reductase inhibitor, b) an antioxidant, and c) hyaluronic acid for cosmetic purposes.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 21, 2013
    Applicant: LUCOLAS-M.D. LTD.
    Inventor: Alfred Schmidt
  • Publication number: 20130309218
    Abstract: The purpose of the present invention is to provide a process for producing an aqueous solution containing a fat-soluble substance. A combination of a super dissolution aid, cyclodextrin and a fat-soluble substance or a combination of the super dissolution aid and a cyclodextrin complex of the fat-soluble substance is used for dissolving the fat-soluble substance, whereby it becomes possible to provide an aqueous solution containing the fat-soluble substance at a high concentration and an aqueous solution having improved transdermal absorbability of the fat-soluble substance contained therein.
    Type: Application
    Filed: January 31, 2012
    Publication date: November 21, 2013
    Applicant: WACKER CHEMIE AG
    Inventors: Keiji Terao, Hiroshi Fukumi, Daisuke Nakata, Yukiko Uekaji, Ayako Jo
  • Patent number: 8586625
    Abstract: A cytotoxic composition in which two moieties are conjugated covalently. A first moiety is a tax moiety, selected from the group consisting of taxanes, taxane derivatives, and or other closely relative compounds. A second moiety is an acid moiety selected from the group consisting of lipoic acid, acetylcysteine, compounds having an acidic group.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 19, 2013
    Inventors: Anwar Rayan, Taher Nassar
  • Publication number: 20130281521
    Abstract: The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of antioxidants and mitochondrial cofactors in amounts sufficient for preventing or treating kidney disease or for improving kidney function and methods for preventing and treating kidney disease or improving kidney function comprising administering such compositions to an animal susceptible to or suffering from kidney disease or impaired kidney function. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease and improving kidney function, particularly in senior animals.
    Type: Application
    Filed: June 20, 2013
    Publication date: October 24, 2013
    Inventors: Steven Curtis Zicker, Karen Joy Wedekind
  • Publication number: 20130281520
    Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Julio Cesar Castro Palomino Laria
  • Publication number: 20130273163
    Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.
    Type: Application
    Filed: October 10, 2012
    Publication date: October 17, 2013
    Inventors: Matthias SEILER, Norbert Windhab, Manfred Stickler, Hans-Ulrich Petereit
  • Publication number: 20130251647
    Abstract: The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.
    Type: Application
    Filed: September 20, 2012
    Publication date: September 26, 2013
    Applicant: BASF SE
    Inventors: Thomas Subkowski, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel, Ralf Pelzer
  • Publication number: 20130251697
    Abstract: Systems and methods are disclosed for treating a plurality of sinsousal conditions to be treated. These systems and methods include selecting a combination of at least two compounds that are capable of addressing a plurality of sinsousal conditions. At least one of the at least two compounds is selected from a group of anti fungals, antioxidants, and chelators. These systems and methods also include verifying that the compounds are biologically compatible and creating a combination compound using the selected compounds.
    Type: Application
    Filed: December 5, 2012
    Publication date: September 26, 2013
    Inventor: Ford D. Albritton, IV
  • Patent number: 8541601
    Abstract: The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: September 24, 2013
    Assignees: Celltrion Chemical Research Institute, Celltrion Pharm, Inc.
    Inventors: Kyoung Soo Kim, Young Jun Park, Hyun-Nam Song, In Suk Lee, Joon Woo Kim
  • Patent number: 8541465
    Abstract: Formulations comprising docetaxel or a salt thereof in combination with ?-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more efficient use of personnel in infusion preparation.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: September 24, 2013
    Assignee: SciDose, LLC
    Inventor: Nageswara R. Palepu
  • Patent number: 8535647
    Abstract: Cosmetic/sunscreen compositions contain a combination of at least one dibenzoylmethane sunscreen compound and a photostabilizing amount of at least one dithiolane compound of formula (I) below:
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: September 17, 2013
    Assignee: L'Oreal
    Inventors: Karine Lucet-Levannier, Benoit Muller
  • Patent number: 8536222
    Abstract: The present invention provides new addition compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, alpha-ketoglutaric acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These addition compounds have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the addition compounds come to the fore.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: September 17, 2013
    Assignee: AlzChem AG
    Inventors: Thomas Gastner, Hans-Peter Krimmer
  • Publication number: 20130237483
    Abstract: The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (la) or compositions comprising compounds of Structural Formulas (I) and (la), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.
    Type: Application
    Filed: November 10, 2011
    Publication date: September 12, 2013
    Inventors: Alexander B. Baguisi, Reinier Beeuwkes, Ralph Casale, Steven A. Kates, Alan S. Lader
  • Patent number: 8530511
    Abstract: Dithiolane compounds having the structural formula (I): are useful for reinforcing and/or preserving the natural antioxidant protection of the skin against oxidative stress caused, especially, by UV radiation, e.g., by increasing the level of intracellular glutathione.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: September 10, 2013
    Assignee: L'Oreal
    Inventors: Xavier Marat, Karine Lucet-Levannier, Laurent Marrot
  • Patent number: 8501801
    Abstract: Disclosed is, for example, a compound that can be a material which can control many functions. According to a first aspect of the present invention, there is provided an organic semiconductor compound characterized in that the organic semiconductor compound is produced by forming a salt of organic molecules as a donor with an inorganic acid or an inorganic base and causes self-accumulation. According to the above constitution, the organic semiconductor compound can be obtained in a simple manner. According to a second aspect of the present invention, there is provided an organic compound characterized by being produced by deriving an ammonia salt or a hydroxyamine salt from a compound having a tetrathiafulvalene analogue site in the skeleton thereof and containing a protonic acid functional group. According to the above constitution, an organic compound which can control many functions can be obtained.
    Type: Grant
    Filed: February 15, 2009
    Date of Patent: August 6, 2013
    Assignee: National Institute for Materials Science
    Inventors: Kazuhiko Saigo, Yuka Kobayashi
  • Publication number: 20130190327
    Abstract: The invention relates to bis-fatty acid conjugates; compositions comprising an effective amount of a bis-fatty acid conjugate; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a bis-fatty acid conjugate.
    Type: Application
    Filed: February 25, 2011
    Publication date: July 25, 2013
    Applicant: CATABASIS PHARMACEUTICALS INC
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: 8492421
    Abstract: The invention relates to a therapeutic agent for fungal dermatitis, containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, and a composition for the treatment of fungal dermatitis, containing luliconazole or lanoconazole in a substantially dissolved state as an active ingredient.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: July 23, 2013
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Hiroyasu Koga, Yasuko Nanjoh, Hideo Kaneda
  • Publication number: 20130183281
    Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).
    Type: Application
    Filed: April 20, 2012
    Publication date: July 18, 2013
    Inventors: Shin-San Michael Su, Lenny Dang, Stefan Gross, Shengfang Jin, Valeria Fantin
  • Publication number: 20130183277
    Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.
    Type: Application
    Filed: December 19, 2012
    Publication date: July 18, 2013
    Inventor: Jon D. Kaiser
  • Patent number: 8470861
    Abstract: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: June 25, 2013
    Assignee: University of Rochester
    Inventors: Marion W. Anders, James L. Robotham, Shey-Shing Sheu, Paul Spencer Brookes, Jalil Shojaie, Leif Olson, Richard L. Parton
  • Publication number: 20130157986
    Abstract: Pharmaceutical compounds and compositions are provided which are methylenedioxy phenolic compounds and their derivatives, along with methods of making them and methods of using them for therapeutic purposes. The compounds and compositions are advantageous in that they can be used to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.
    Type: Application
    Filed: June 12, 2012
    Publication date: June 20, 2013
    Applicants: INVASC THERAPEUTICS, INC., OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: SAMPATH PARTHASARATHY, SANJAY RAJAGOPALAN, DESIKAN RAJAGOPAL
  • Publication number: 20130136703
    Abstract: A diffusion rate limiting matrix is utilized to lingually and/or sublingually deliver thioctic acid. This limited release matrix is intended for general nutritional supplementation and/or the treatment of various physiological disorders. Due to its lingual nature, this rate limiting matrix can produce IV-equivalent plasma levels and is not meant to be swallowed.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 30, 2013
    Inventor: Jeffery Lee Benjamin, JR.
  • Publication number: 20130121981
    Abstract: A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars, purpura, skin firming, muscle, tendon and ligament improvement and repair, and hair conditions, among other skin diseases or conditions.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 16, 2013
    Inventor: David L. Kaplan
  • Publication number: 20130116312
    Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
    Type: Application
    Filed: December 18, 2009
    Publication date: May 9, 2013
    Applicant: PHENOMENOME DISCOVERIES INC.
    Inventors: M. KHAN, Paul WOOD, Dayan GOODENOWE, Rishikesh MANKIDY, Pearson AHIAHONU
  • Publication number: 20130096187
    Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) crotamiton.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 18, 2013
    Applicants: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Nihon Nohyaku Co., Ltd., Pola Pharma Inc.
  • Patent number: 8410162
    Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: April 2, 2013
    Assignee: Encore Health LLC
    Inventors: William Garner, Margaret Garner, George Minno, David Gooden